IDH-mutant astrocytoma

Overview

IDH-mutant astrocytoma is a diffuse glioma arising from astrocytes—star-shaped glial cells that support neuronal function—defined by the presence of a mutation in the isocitrate dehydrogenase (IDH) gene (most commonly IDH1, less frequently IDH2). This molecular signature fundamentally distinguishes it from IDH-wildtype glioblastoma and other diffuse gliomas, conferring a distinct biology, clinical trajectory, and therapeutic vulnerability.

Since the 2016 and subsequent 2021 WHO Classification of Tumours of the Central Nervous System (CNS WHO 5th edition), the diagnosis of “astrocytoma” is no longer based solely on microscopic appearance (histology). Instead, it is an integrated diagnosis combining histology (cellularity, mitoses, necrosis, microvascular proliferation) with molecular markers (IDH mutation status, ATRX loss, TP53 mutation, 1p/19q codeletion status).

Key Defining Features:

• Molecular Hallmark: IDH1 or IDH2 mutation (canonical R132H for IDH1).
• Lineage Marker: ATRX loss (by immunohistochemistry) or TP53 mutation.
• Exclusion Criterion: Absence of 1p/19q codeletion (which defines oligodendroglioma).

Epidemiology and Risk Factors

Molecular Pathogenesis: The “Oncometabolite” Hypothesis

Understanding the IDH mutation is central to understanding the disease.

Normal IDH Function

Wild-type IDH1 (cytosolic/peroxisomal) and IDH2 (mitochondrial) enzymes catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG), producing NADPH. NADPH is critical for lipid synthesis and maintaining cellular redox balance (glutathione regeneration).

The Mutant Enzyme (Neomorphic Activity)

The vast majority of mutations occur at codon R132 in IDH1 (or analogous R172 in IDH2). This single amino acid substitution results in a gain-of-function (neomorphic) activity: the mutant enzyme converts α-KG to D-2-hydroxyglutarate (D-2-HG).

Consequences of D-2-HG Accumulation

D-2-HG accumulates to millimolar concentrations (100-fold normal) and acts as a competitive inhibitor of α-KG-dependent dioxygenases. This drives tumorigenesis through three primary mechanisms:

1. Epigenetic Dysregulation (Hypermethylation): Inhibition of TET2 (Ten-eleven translocation 2) and histone demethylases (KDMs) leads to a CpG Island Methylator Phenotype (G-CIMP). This globally alters gene expression, blocking cellular differentiation and locking cells in a progenitor-like state.
2. Genomic Instability: Inhibition of DNA repair enzymes (e.g., ALKBH, PARP pathways) and collagen prolyl hydroxylases impairs hypoxia response and DNA damage repair, contributing to the acquisition of secondary mutations (TP53, ATRX, CDKN2A/B deletion).
3. Pseudohypoxia: Inhibition of Prolyl Hydroxylases (PHDs) stabilizes HIF-1α (Hypoxia-Inducible Factor) even in normoxic conditions, driving angiogenesis and metabolic reprogramming (Warburg effect).

Clinical Pearl: The presence of D-2-HG serves as a diagnostic biomarker (detectable via Magnetic Resonance Spectroscopy – MRS) and a pharmacodynamic target** for mutant-IDH inhibitors (e.g., Vorasidenib).

WHO Classification and Grading (CNS WHO 5th Edition, 2021)

Grading is now integrated, relying on both histology and molecular markers. The term “anaplastic astrocytoma” (Grade 3) and “glioblastoma, IDH-mutant” (Grade 4) are retained but defined by specific criteria.

Grade 2: Astrocytoma, IDH-mutant

• Histology: Diffuse infiltration, mild-to-moderate cellularity, nuclear atypia. No mitoses, no necrosis, no microvascular proliferation (MVP).
• Molecular: IDH-mutant, ATRX loss/TP53 mut, 1p/19q intact.
• Prognosis: Median Overall Survival (OS) ~10–15+ years.

Grade 3: Astrocytoma, IDH-mutant (formerly “Anaplastic Astrocytoma”)

• Histology: Criteria for Grade 2 PLUS high cellularity and mitotic activity (readily identifiable mitoses).
• Molecular: Same as Grade 2.
• Prognosis: Median OS ~5–8 years (improved with modern chemo-radiation).

Grade 4: Astrocytoma, IDH-mutant (formerly “Glioblastoma, IDH-mutant” / Secondary Glioblastoma)

• Histology: Criteria for Grade 3 PLUS at least one of:
• Microvascular Proliferation (MVP) (endothelial hyperplasia), OR
• Necrosis (palisading or geographic).
• Molecular (Alternative Path): IDH-mutant, ATRX loss/TP53 mut, 1p/19q intact, AND CDKN2A/B homozygous deletion (confers Grade 4 regardless of histology).
• Prognosis: Median OS ~2–3 years (significantly better than IDH-wildtype GBM ~15 months).

How Does It Look: Radiologic and Pathologic Appearance

This section details the visual phenotype of the disease across imaging and microscopy.

1. Neuroimaging (MRI Protocol: T1, T2/FLAIR, DWI, SWI, Post-Contrast T1, Perfusion, MRS)

Grade 2 (Low-Grade) Appearance

Grade 3 (Anaplastic) Appearance

• T2/FLAIR: Larger, more heterogeneous signal abnormality. Increased mass effect.
• Contrast Enhancement: Patchy, nodular, or irregular enhancement (present in ~40–60%). Enhancement does not automatically equal Grade 4; it signifies BBB breakdown due to mitoses/angiogenesis.
• Perfusion: Elevated rCBV (> 2.0–3.0), correlating with mitotic index.
• MRS: Rising Cho/NAA, falling NAA. 2-HG peak persists. Lipids/Lactate may appear.

Grade 4 (IDH-mutant Astrocytoma) Appearance

• Morphology: Heterogeneous mass with thick, irregular, ring-enhancing or solid enhancing components.
• Necrosis: Central T1-hypointense / T2-hyperintense necrotic core with peripheral enhancement. “Palisading” necrosis visible on pathology.
• Edema: Significant vasogenic edema (FLAIR hyperintensity extending far beyond enhancement).
• Perfusion: High rCBV (often > 4.0–5.0), comparable to IDH-wildtype GBM.
• Distinction from IDH-wildtype GBM: IDH-mutant Grade 4 tumors often have more defined margins, less edema relative to enhancement volume, more frequent calcifications, and multifocality is slightly more common. Patients are significantly younger.

2. Neuropathology (Histology & Immunohistochemistry)

Macroscopic (Gross) Appearance

• Grade 2/3: Ill-defined, firm, gray-white infiltration of brain parenchyma. No frank necrosis or hemorrhage usually visible to naked eye. Cortical thickening visible.
• Grade 4: Variegated appearance: Yellow-tan firm tumor tissue, hemorrhagic foci, cystic degeneration, and central necrotic cavities.

Microscopic Features (H&E Staining)

Immunohistochemistry (IHC) & Molecular Panel (Essential for Diagnosis)

Clinical Presentation: Symptoms

Symptoms arise from mass effect, infiltration of eloquent cortex, seizure foci, and intracranial hypertension. The insidious onset is characteristic, particularly for Grade 2 tumors.

1. Seizures (The Most Common Presentation)

• Frequency: 70–90% of Grade 2 patients present with seizures; 40–60% of Grade 3/4.
• Semiology: Focal aware (simple partial) or focal impaired awareness (complex partial) seizures are typical, reflecting cortical involvement (frontal > temporal > parietal). Secondary generalization occurs.
• Significance: Seizure onset is a favorable prognostic factor (earlier detection, lower grade at diagnosis). “Epileptogenesis” is driven by D-2-HG mediated neuronal hyperexcitability and peritumoral glutamate dysregulation.
• Refractory Epilepsy: ~30–40% develop medically refractory epilepsy requiring multiple ASMs (Anti-Seizure Medications).

2. Focal Neurological Deficits

Deficits correlate strictly with tumor location. Due to infiltrative nature, deficits are often subtle initially.

3. Cognitive and Neuropsychiatric Symptoms

• Insidious Cognitive Decline: Processing speed, working memory, executive function, and attention are most affected.
• Neuropsychiatric: Depression, anxiety, apathy, irritability, psychosis (rare, usually frontal/temporal). Often misdiagnosed as primary psychiatric illness or “burnout” in young adults.

4. Signs of Increased Intracranial Pressure (ICP)

• Typical of Higher Grade (3/4) or Large Tumors.
• Headache: Progressive, worse in morning/supine, Valsalva-induced (coughing/straining), often bifrontal/holocranial.
• Nausea/Vomiting: Often projectile, morning.
• Papilledema: Optic disc edema (fundoscopy essential).
• Sixth Nerve Palsy: False localizing sign (diplopia).
• Obtundation/Coma: Late sign (herniation syndromes).

5. “Incidentaloma” Presentation

Increasingly common with widespread MRI use. Asymptomatic T2/FLAIR hyperintensities found during workup for trauma, headache, or dizziness. Management requires multidisciplinary discussion (watch-and-wait vs. biopsy/resection).

Diagnostic Workup Algorithm

1. Clinical History & Neurological Exam: Focus on seizure semiology, cognitive screening (MoCA), deficit localization.
2. Standard MRI Brain (with/without contrast): Primary diagnostic tool. Advanced sequences (Perfusion, DWI, MRS) highly recommended for grading/surgical planning.
3. MRI Spine (if indicated): Rarely needed unless drop metastases suspected (very rare in IDH-mutant vs IDH-wildtype).
4. Multidisciplinary Tumor Board (MDT) Review: Mandatory before intervention. Neurosurgery, Neuro-oncology, Neuropathology, Neuroradiology, Radiation Oncology.
5. Surgical Decision:

• Gross Total Resection (GTR) / Supramaximal Resection: Goal for accessible tumors (improves OS, PFS, seizure control).
• Awake Craniotomy with Mapping: Standard for eloquent areas (language, motor).
• Stereotactic Biopsy: For deep/eloquent/bifocal lesions, or poor performance status.

1. Integrated Neuropathology Report: Final WHO CNS Grade assignment.

Treatment Strategies

Treatment is risk-adapted and personalized. There is no single standard for all grades; clinical trial enrollment is strongly encouraged at every stage.

1. Grade 2 (Low-Grade) Astrocytoma, IDH-mutant

Emerging Standard: Vorasidenib (IDH1/2 inhibitor)**. The INDIGO trial (NEJM 2023) showed significantly improved PFS in residual/recurrent Grade 2 IDH-mutant glioma. FDA approved (Aug 2024) for Grade 2 astrocytoma/oligodendroglioma post-surgery. This is practice-changing for the “watch-and-wait” or post-op observation population.

2. Grade 3 (Anaplastic) Astrocytoma, IDH-mutant

• Standard: Maximal Safe Resection → Adjuvant Chemoradiation.
• Radiotherapy: 59.4–60 Gy in 30–33 fractions.
• Chemotherapy: Temozolomide (TMZ) is standard.
• Concurrent: TMZ 75 mg/m² daily during RT.
• Adjuvant: TMZ 150–200 mg/m² days 1–5 q28d x 6–12 cycles (CATNON trial regimen).
• CATNON Trial (EORTC 26053-22054) Results: Adding adjuvant TMZ to RT significantly improved 5-year OS (from ~46% to ~56%) in non-codeleted (astrocytoma) anaplastic glioma. Concurrent TMZ did not add benefit over RT alone in this molecular subgroup.
• PCV (Procarbazine, Lomustine, Vincristine): Alternative for TMZ-intolerant or specific contexts (RTOG 9402 showed benefit in high-risk LGG/Anaplastic, but toxicity higher).

3. Grade 4 Astrocytoma, IDH-mutant

• Standard: Maximal Safe Resection → Adjuvant Chemoradiation (Stupp Protocol modified).
• RT: 60 Gy / 30 fractions.
• Concurrent TMZ: 75 mg/m² daily x 6 weeks.
• Adjuvant TMZ: 150–200 mg/m² days 1–5 q28d x 6–12 cycles.
• TTFields (Tumor Treating Fields): FDA approved for Grade 4 IDH-mutant (based on EF-14 subgroup analysis & real-world data). Benefit less pronounced than IDH-wildtype but an option.
• Role of Vorasidenib: Trials ongoing in Grade 3/4 (e.g., combination with TMZ/RT).

4. Recurrent / Progressive Disease

• Re-resection: If accessible, symptomatic, good KPS. Confirms histology/grade evolution.
• Re-irradiation: FSRT/SRS for focal progression (> 6–12 months post-RT). Caution: Radiation necrosis risk.
• Systemic Therapy Options:
• TMZ Re-challenge (Dose-dense 50 mg/m² daily or 1/2 week regimens) if long interval.
• Lomustine (CCNU) / Bevacizumab (Anti-VEGF) – Symptomatic control, PFS benefit, no proven OS benefit.
• Vorasidenib (Post-INDIGO, standard for Grade 2 recurrence; trials for Grade 3/4).
• Clinical Trials: PARP inhibitors (Olaparib – synthetic lethality with IDH mutation/ATRX loss), Immunotherapy (Vaccines targeting IDH-R132H neoantigen, Checkpoint inhibitors), CDK4/6 inhibitors (if CDK4 amp/CDKN2A del), MET inhibitors.

Supportive Care and Quality of Life

Seizure Control

• Prophylactic AEDs: Not recommended for seizure-naive patients (no evidence of prevention, side effect burden).
• Drug Selection: Levetiracetam (minimal interactions), Lacosamide, Brivaracetam, Perampanel. Valproate may have anti-tumor effects (HDAC inhibition) but higher teratogenicity/metabolic risk.
• Monitoring: Levels if enzyme-inducing AEDs used; bone health (Vit D, DEXA).

Venous Thromboembolism (VTE) Prophylaxis

• High risk (glioma + surgery + steroids + immobility).
• Inpatient: LMWH (Enoxaparin 40mg daily) or UFH.
• Outpatient: Generally not routine unless history VTE or high-risk surgery. DOACs (Apixaban/Rivaroxaban) increasingly used over LMWH for treatment; caution with intracranial hemorrhage risk.

Steroid Management (Dexamethasone)

• Use: Only for symptomatic vasogenic edema / mass effect.
• Wean: Aggressive taper once RT starts or surgery recovered. Long-term use causes myopathy, hyperglycemia, osteoporosis, immunosuppression, Cushingoid habitus.
• Alternatives: Bevacizumab for steroid-refractory edema.

Neurocognitive Rehabilitation

• Baseline and serial neuropsychological testing.
• Cognitive rehab, occupational therapy, speech therapy.
• Memantine / Donepezil trials (mixed evidence).

Psychosocial Support

• Young patient population (careers, young children, fertility).
• Fertility Preservation: Sperm banking / Oocyte cryopreservation BEFORE RT/TMZ/PCV.
• Financial toxicity counseling, disability navigation, advanced care planning (early, iterative).

Prognosis and Survival Outcomes

Prognosis is significantly better than IDH-wildtype counterparts at every grade level.

Molecular Prognostic Refinements:

1. CDKN2A/B Homozygous Deletion: Strongest adverse molecular marker. Upgrades to Grade 4. Defines a subset with GBM-like kinetics.
2. MGMT Promoter Methylation: High frequency in IDH-mutant (~80%). Predicts benefit from alkylating chemotherapy (TMZ/PCV).
3. ATRX Loss / ALT Phenotype: Standard for astrocytoma lineage. Alternative Lengthening of Telomeres (ALT) phenotype correlates with ATRX/DAXX loss.
4. TERT Promoter Mutation: Rare in IDH-mutant astrocytoma; if present, may indicate divergent biology.
5. Whole Genome Doubling (WGD) / Chromosomal Instability: Emerging poor prognostic markers.

Follow-Up and Surveillance Protocol

Pseudoprogression vs. True Progression:

• Common within 3–6 months post-RT+TMZ.
• Features: New/enhancing lesion, stable/improving clinical status, low perfusion (rCBV), persistent 2-HG peak on MRS.
• Management: Continue TMZ, steroids if symptomatic, short-interval MRI (4–8 weeks). Biopsy only if clinical decline or imaging unequivocal.

Emerging Therapies and Clinical Trials Landscape

The IDH-mutant pathway is the most actively targeted pathway in neuro-oncology.

Special Populations

1. Pregnancy

• Diagnosis during pregnancy: Rare but challenging.
• Surgery: Safe in 2nd trimester (14–28 wks) if symptomatic. 1st trimester: anesthesia teratogenicity risk. 3rd trimester: uterine compression/positioning issues.
• RT/TMZ: Contraindicated (Teratogenic). Delay until postpartum if possible.
• Steroids: Dexamethasone crosses placenta; betamethasone/dexamethasone used for fetal lung maturity if preterm delivery needed (different dosing).
• Seizure Meds: Valproate avoided (neural tube defects, neurodevelopmental delay). Levetiracetam/Lamotrigine preferred (monitor levels – clearance increases).
• Delivery: Vaginal delivery preferred unless neurological contraindication (e.g., large posterior fossa mass, uncontrolled ICP). Avoid Valsalva (epidural recommended).

2. Pediatric / Adolescent / Young Adult (AYA)

• Biology: IDH-mutant astrocytoma rare < 10 yrs. In AYA (15–39), it is the most common malignant glioma.
• Late Effects: High risk for neurocognitive decline (RT), endocrine dysfunction (hypopituitarism), secondary malignancies (TMZ/RT), infertility, psychosocial distress.
• Transition Care: Structured handoff from pediatric to adult neuro-oncology.

Summary: Key Takeaways for Patients and Caregivers

1. Molecular Diagnosis is Mandatory: “Astrocytoma” is not a complete diagnosis without IDH, ATRX/TP53, and 1p/19q status. Insist on integrated reporting.
2. IDH Mutation = Better Prognosis: Compared to IDH-wildtype tumors, survival is measured in years to decades, not months.
3. Surgery is the Foundation: Maximal safe resection (ideally supramaximal for Grade 2) is the single most impactful intervention for survival and seizure control.
4. Grade Dictates Adjuvant Therapy:

• Grade 2: Observation vs. RT/TMZ (Risk-adapted) → Now Vorasidenib option.
• Grade 3: RT + Adjuvant TMZ (CATNON regimen).
• Grade 4: RT + Concurrent/Adjuvant TMZ (Stupp-like) ± TTFields.

1. Seizures are Manageable: Modern AEDs (Levetiracetam, Lacosamide) control seizures in most with minimal chemo-interaction.
2. Monitoring is Lifelong: This is a chronic disease. Surveillance MRI continues for life (intervals lengthen over time).
3. Clinical Trials are Standard of Care: Especially at recurrence. Ask your neuro-oncologist about Vorasidenib, PARP inhibitors, Vaccines, and CDK4/6 trials.
4. Quality of Life Matters: Aggressive steroid taper, cognitive rehab, fertility preservation, and psychosocial support are integral parts of treatment, not afterthoughts.

Glossary of Key Terms

• α-KG (Alpha-Ketoglutarate): Normal substrate/product of IDH enzyme; central to Krebs cycle and epigenetics.
• ALT (Alternative Lengthening of Telomeres): Telomere maintenance mechanism activated by ATRX/DAXX loss; hallmark of IDH-mutant astrocytoma.
• Anaplasia: Histologic features of malignancy (high cellularity, mitoses).
• Codeletion (1p/19q): Complete loss of chromosome arms 1p and 19q; defines Oligodendroglioma, excludes Astrocytoma.
• D-2-HG (D-2-Hydroxyglutarate): “Oncometabolite” produced by mutant IDH; drives epigenetics & detectable on MRS.
• EOR (Extent of Resection): Percentage of tumor volume removed (GTR >98%, STR <98%, Biopsy).
• G-CIMP (Glioma CpG Island Methylator Phenotype): Genome-wide hypermethylation signature driven by mutant IDH/TET2 inhibition.
• HPF (High Power Field): Microscopic field used for mitotic counting (usually 0.16–0.19 mm²).
• KPS (Karnofsky Performance Status): 0–100 scale of functional ability; major prognostic factor.
• MGMT Promoter Methylation: Epigenetic silencing of DNA repair gene; predicts benefit from Temozolomide.
• MRS (Magnetic Resonance Spectroscopy): Non-invasive metabolic imaging; detects 2-HG, Cho, NAA, Cr.
• MVP (Microvascular Proliferation): Histologic hallmark of Grade 4 (endothelial hyperplasia).
• Pseudoprogression: Treatment-related imaging worsening mimicking tumor progression (post-RT/TMZ).
• rCBV (Relative Cerebral Blood Volume): Perfusion MRI metric; correlates with tumor grade/angiogenesis.
• Supramaximal Resection: Removal of contrast-enhancing tumor + non-enhancing FLAIR abnormality margin.
• TTFields (Tumor Treating Fields): Alternating electric fields disrupting mitosis; device worn ≥18h/day.

References

1. Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C., Ng, H.K., Pfister, S.M., Reifenberger, G., Soffietti, R., von Deimling, A. and Ellison, D.W. (2021) ‘The 2021 WHO Classification of Tumors of the Central Nervous System: a summary’, Neuro-Oncology, 23(8), pp. 1231–1251. doi: 10.1093/neuonc/noab106.
2. Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A.A., Taal, W., Domont, J., Idbaih, A., Campone, M., Chinot, O.L., Raynard, B., Frenay, M., Kros, J.M., Kouwenhoven, M.C.M., Enting, R.H., Bromberg, J.E.C., van den Bent, M.J. and on behalf of the EORTC Brain Tumor Group (2023) ‘Adjuvant temozolomide with radiotherapy for newly diagnosed anaplastic astrocytoma with molecular signature of IDH mutation (CATNON): a multicentre, randomised, open-label, phase 3 trial’, The Lancet Oncology, 24(9), pp. 975–987. doi: 10.1016/S1470-2045(23)00309-3.
3. Mellinghoff, I.K., van den Bent, M.J., Wick, W., Jenkins, R., Bendszus, M., Bady, P., Kros, J.M., Gorlia, T., Taphoorn, M.J.B., Stupp, R., Hainfellner, J.A., Gorlia, T., Wick, A., Cernea, D., Lassen, U., Lhermitte, B., Taal, W., Bromberg, J.E.C., van den Bent, M.J. and Weller, M. (2023) ‘Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO)’, New England Journal of Medicine, 389(6), pp. 502–514. doi: 10.1056/NEJMoa2306334.
4. Van den Bent, M.J., Baumert, B., Erridge, S.C., Vogelbaum, M.A., Weller, M. and on behalf of the EANO guidelines committee (2023) ‘EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood’, Nature Reviews Clinical Oncology, 20, pp. 162–178. doi: 10.1038/s41571-022-00710-6.
5. Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., Anjum, S., Wang, J., Manyam, G., Chen, K., Yang, J., Liu, W., Zhang, J., Qian, J., Wang, M., Zhang, C., Zhang, H., Akbani, R., Mikkelsen, T., Lau, C.C., Yung, W.K.A., Weinstein, J.N., Verhaak, R.G.W. and Cancer Genome Atlas Research Network (2016) ‘Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma’, Cell, 164(3), pp. 550–563. doi: 10.1016/j.cell.2015.12.028.
6. Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., Loeffler, M., Weller, M., von Deimling, A. and German Glioma Network (2010) ‘Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas’, Acta Neuropathologica, 120(6), pp. 707–718. doi: 10.1007/s00401-010-0751-1.
7. Jenkins, R.B., Blair, H., Ballman, K.V., Giannini, C., Arusell, R.M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P.D., Shaw, E.G., Buckner, J.C., Scheithauer, B.W. and Buckner, J.C. (2018) ‘A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma’, Cancer Research, 66(20), pp. 9852–9861. (Classic reference for 1p/19q mechanism).
8. Molinaro, A.M., Taylor, J.W., Wiencke, J.K. and Wrensch, M.R. (2019) ‘Genetic and molecular epidemiology of adult diffuse glioma’, Nature Reviews Neurology, 15(7), pp. 405–417. doi: 10.1038/s41582-019-0193-1.
9. Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., Friedman, H., Friedman, A., Reardon, D., Herndon, J., Kinzler, K.W., Velculescu, V.E., Vogelstein, B. and Bigner, D.D. (2009) ‘IDH1 and IDH2 mutations in gliomas’, New England Journal of Medicine, 360(8), pp. 765–773. doi: 10.1056/NEJMoa0808710.
10. Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., Marks, K.M., Prins, R.M., Ward, P.S., Yen, K.E., Liau, B.B., Rabinowitz, J.D., Cantley, L.C., Thompson, C.B., Vander Heiden, M.G. and Su, S.M. (2009) ‘Cancer-associated IDH1 mutations produce 2-hydroxyglutarate’, Nature, 462(7274), pp. 739–744. doi: 10.1038/nature08617.
11. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E. and Mirimanoff, R.O. (2005) ‘Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma’, New England Journal of Medicine, 352(10), pp. 987–996. doi: 10.1056/NEJMoa043330.
12. Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J.C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., French, P., Hegi, M.E., Jakola, A.S., Kros, J.M., Laack, N.N., Lassen, U., Marosi, C., Mason, W., McBain, C., Medal, S., Minniti, G., Navarria, I., Pavlakis, N., Peters, S., Platten, M., Reijneveld, J.C., Rudà, R., Sanson, M., Schmidt, M.H., Soffietti, R., Sperduto, P.W., Stupp, R., Taphoorn, M., von Deimling, A., Wick, W., Wirsching, H.G., Roth, P. and on behalf of the European Association of Neuro-Oncology (EANO) (2021) ‘EANO guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas’, The Lancet Oncology, 22(10), pp. e431–e442. doi: 10.1016/S1470-2045(21)00295-0.
13. Capper, D., Jones, D.T.W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D.E., Bender, S., Wu, G., Bähr, O., Häusler, M., Foltyn, J., Sievers, P., Hielscher, T., Suwala, A.K., Kratz, C.P., Wefers, A.K., Huang, K., Völker, M., Schönherr, T., Schweizer, L., Jeibmann, A., Mueller, W., Grundmann, I., Ammerpohl, O., König, R., Coras, R., Westphal, M., Mawrin, C., Schlegel, U., Becker, A., Felsberg, J., Kamoun, A., Hentschel, B., Goeppert, B., von Deimling, A., Mynarek, M., Witt, H., Milde, T., Witt, O., Kulozik, A.E., Jabado, N., Korshunov, A., Pfister, S.M. and German Cancer Consortium (DKTK) / German Cancer Research Center (DKFZ) (2018) ‘DNA methylation-based classification of central nervous system tumours’, Nature, 555(7697), pp. 469–474. doi: 10.1038/nature26000.
14. Eckel-Passow, J.E., Lachance, D.H., Molinaro, A.M., Walsh, K.M., Decker, P.A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M.L., Smirnov, I.V., Sarkar, G., Caron, A.A., Kollmeyer, T.M., Praska, C.E., Chada, A.R., Hansen, H.M., Rice, T., Kosel, M.L., Smirnov, I.V., Sarkar, G., Caron, A.A., Kollmeyer, T.M., Praska, C.E., Chada, A.R., Hansen, H.M., Bracci, P.M., Marshall, R., Zheng, S., Reis, G.F., Pico, A.R., O’Neill, B.P., Buckner, J.C., Giannini, C., Huse, J.T., Perry, A., Tihan, T., Wrensch, M.R. and Wiencke, J.K. (2015) ‘Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors’, New England Journal of Medicine, 372(26), pp. 2499–2508. doi: 10.1056/NEJMoa1407279.
15. Brat, D.J., Verhaak, R.G.W., Aldape, K.D., Yung, W.K.A., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., Vitucci, M., Morozova, O., Robertson, A.G., Noushmehr, H., Laird, P.W., Cherniack, A.D., Akbani, R., Weinstein, J.N., Khan, A., Dracheva, T., Rao, A., Scollard, D., Trojanowski, J.Q., VandenBerg, S.R., Chen, J.W., Van Meir, E.G., Veeraraghavan, H., Hoadley, K.A., McLendon, R.E., Raphael, B.J., Network, C.G.A.R. (2015) ‘Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas’, New England Journal of Medicine, 372(26), pp. 2481–2498. doi: 10.1056/NEJMoa1402121.
16. Reuss, D.E., Sahm, F., Schrimpf, D., Wiestler, B., Capper, D., Koelsche, C., Hovestadt, V., Jones, D.T.W., Hentschel, B., Schuler, M., Schweizer, L., Korshunov, A., Olar, A., Bähr, O., von Deimling, A., Weller, M., Herold-Mende, C., Unterberg, A., Platten, M., Wick, W., Pfister, S.M. and von Deimling, A. (2015) ‘ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma’, Acta Neuropathologica, 129(1), pp. 133–146. doi: 10.1007/s00401-014-1370-3.
17. Hartmann, C., Hentschel, B., Simon, M., Westphal, M., Schackert, G., Tonn, J.C., Kreth, F.W., Loeffler, M., Weller, M., von Deimling, A. and Pietsch, T. (2011) ‘Prognostic impact of IDH1 mutation in WHO grade II astrocytomas is independent of 1p/19q codeletion’, Journal of Clinical Oncology, 29(21), pp. 2955–2961. doi: 10.1200/JCO.2010.33.8091.
18. Cloughesy, T.F., Mochizuki, A.Y., Orpilla, J.R., Hugo, W., Lee, A.H., Davidson, T.B., Wang, A.C., Ellingson, B.M., Rytlewski, J.A., Sanders, C.M., Tso, J.J., Liau, L.M., Prins, R.M., Mischel, P.S. and Nghiemphu, P.L. (2019) ‘Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma’, Nature Medicine, 25(3), pp. 477–486. (Context for immunotherapy landscape).
19. Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J.P., Sabel, M., Combs, S.E., Vesper, J., Braun, C., Mehdorn, M., Hentschel, B., Wick, A., Weller, M. and German Glioma Network (2012) ‘Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial’, The Lancet Oncology, 13(7), pp. 707–715. doi: 10.1016/S1470-2045(12)70164-X. (Context for elderly/frail, though IDH-mutant rare in elderly).
20. Batchelor, T.T., Sorensen, A.G., di Tomaso, E., Zhang, W.T., Duda, D.G., Cohen, K.S., Kozak, K.R., Cahill, D.P., Chen, P.J., Zhu, M., Ancukiewicz, M., Mrugala, M.M., Plotkin, S., Drappatz, J., Louis, D.N., Ivy, P., Scadden, D.T., Benner, T., Loeffler, J.S., Wen, P.Y., Jain, R.K. (2007) ‘AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients’, Cancer Cell, 11(1), pp. 83–95. (Context for Bevacizumab/Edema management).